Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C31H29N3O5S2 |
| Molecular Weight | 587.709 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NOC(=N1)C(=C\C2=CC(=CC=C2)C3=CC(=CC4=CC=CN=C34)C(C)(C)S(C)(=O)=O)\C5=CC=C(C=C5)S(C)(=O)=O
InChI
InChIKey=YYGZHVJDHMMABU-OGLMXYFKSA-N
InChI=1S/C31H29N3O5S2/c1-20-33-30(39-34-20)28(22-11-13-26(14-12-22)40(4,35)36)17-21-8-6-9-23(16-21)27-19-25(31(2,3)41(5,37)38)18-24-10-7-15-32-29(24)27/h6-19H,1-5H3/b28-17+
MK-0359 (L-454560) is a selective and potent type 4 phosphodiesterases (PDE4) inhibitor, which binds to both the apo-(Mg2+-free) and holoenzyme states of PDE4. This compound successfully has passed the phase II clinical trial for the treatment of asthma, Pulmonary Disease, Chronic Obstructive (COPD) and Rheumatoid Arthritis. However, there is no information about the further research of this drug.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P27815|||Q8WUQ3 Gene ID: 5141.0 Gene Symbol: PDE4A Target Organism: Homo sapiens (Human) |
1.6 nM [IC50] | ||
Target ID: Q07343 Gene ID: 5142.0 Gene Symbol: PDE4B Target Organism: Homo sapiens (Human) |
0.5 nM [IC50] | ||
Target ID: Q08499|||Q8IVD2 Gene ID: 5144.0 Gene Symbol: PDE4D Target Organism: Homo sapiens (Human) |
1.2 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3367 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19135348 |
15 mg 1 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
MK-0359 blood | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| In silico pharmacology suggests ginger extracts may reduce stroke risks. | 2011-09 |
|
| Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors. | 2009-09-01 |
|
| Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma. | 2009-03 |
|
| L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition. | 2007-06-15 |
Sample Use Guides
MK-0359 (15mg/day) or placebo for 14 days, then crossed-over to the other treatment for 14 days
Route of Administration:
Oral
L-454,560 (MK-0359) is a potent, competitive and preferential inhibitor of PDE4A, 4B, and 4D with IC50 values of 1.6, 0.5 and 1.2 nM, respectively. L-454,560 binds to both the apo-(Mg2+-free) and holoenzyme states of PDE4. The intrinsic enzyme potency for PDE4 inhibition by L-454,560 also results in an effective blockade of LPS-induced TNFalpha formation in whole blood (IC50 = 161 nM) and is comparable to the human whole blood potency of roflumilast. The cytokine profile of inhibition of L-454,560 is mainly a Th1 profile with significant inhibition of IFNgamma and no detectable inhibition of IL-13 formation up to 1 microM.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
346629-30-9
Created by
admin on Mon Mar 31 23:01:10 GMT 2025 , Edited by admin on Mon Mar 31 23:01:10 GMT 2025
|
PRIMARY | |||
|
G6GSO9SDNJ
Created by
admin on Mon Mar 31 23:01:10 GMT 2025 , Edited by admin on Mon Mar 31 23:01:10 GMT 2025
|
PRIMARY | |||
|
9853498
Created by
admin on Mon Mar 31 23:01:10 GMT 2025 , Edited by admin on Mon Mar 31 23:01:10 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
